Nammi Therapeutics
Biotechnology, Wilshire BLVD, Los Angeles, , 90024, California, 10940, United States, 1-10 Employees
Phone Number: +13*********
Who is NAMMI THERAPEUTICS
Nammi Therapeutics, Inc. is an immuno-oncology company based in Los Angeles that is developing platforms and products that selectively activate anti-tumor immunity within the tumor microe...
Read More
-
Headquarters: 10940 Wilshire BLVD, Los Angeles, California, 90024, United States
-
Date Founded: 2018
-
Employees: 1-10
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 325414 |
Show More
Does something look wrong? Fix it. | View contact records from NAMMI THERAPEUTICS
Nammi Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Nammi Therapeutics
Answer: Nammi Therapeutics's headquarters are located at Wilshire BLVD, Los Angeles, , 90024, California, 10940, United States
Answer: Nammi Therapeutics's phone number is +13*********
Answer: Nammi Therapeutics's official website is https://nammirx.com
Answer: Nammi Therapeutics's revenue is Under $1 Million
Answer: Nammi Therapeutics's SIC: 2836
Answer: Nammi Therapeutics's NAICS: 325414
Answer: Nammi Therapeutics has 1-10 employees
Answer: Nammi Therapeutics is in Biotechnology
Answer: Nammi Therapeutics contact info: Phone number: +13********* Website: https://nammirx.com
Answer: Nammi Therapeutics, Inc. is an immuno-oncology company based in Los Angeles that is developing platforms and products that selectively activate anti-tumor immunity within the tumor microenvironment while minimizing systemic activation. By reducing systemic activation of the immune system, Nammi expects to improve safety and enhance the ability to combine multiple immune modulators. Nammis lead product candidate, QXL138AM, is a Masked Immunocytokine (MIC) targeting a masked interferon to the tumor antigen, CD138. In addition to the MIC platform, Nammi has also developed a nanoparticle platform to deliver Immune Modulating Prodrugs (IMPs) using their Nammisome technology. Multiple Nammisome clinical candidates have also been selected for development.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month